Companies in the multi-billion dollar psoriasis market are vying to be the next standard of treatment, and a flood of new data from three drugs showing them superior to Humira and Stelara.

“Interchangeability of Selarsdi with Stelara will further enable increased access for US patients to more affordable treatment options and contribute to lowering health care costs, which is an ...

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the ...

Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

“Interchangeability of SELARSDI with Stelara will ... the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for ...

including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn’s disease, and ulcerative colitis. “The FDA’s confirmation of full ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...